Type 2 Diabetes Mellitus: Outpatient Insulin Management

Amanda Howard-Thompson, Muneeza Khan, Morgan Jones, Christa George

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In patients with type 2 diabetes mellitus, insulin may be used to augment therapy with oral glycemic medications or as insulin replacement therapy. The American Diabetes Association suggests the use of long-acting (basal) insulin to augment therapy with one or two oral agents or one oral agent plus a glucagon-like peptide 1 receptor agonist when the A1C level is 9% or more, especially if the patient has symptoms of hyperglycemia or catabolism. Insulin regimens should be adjusted every three or four days until targets of self-monitored blood glucose levels are reached. A fasting and premeal blood glucose goal of 80 to 130 mg per dL and a two-hour postprandial goal of less than 180 mg per dL are recommended. Insulin use is associated with hypoglycemia and weight gain. Insulin analogues are as effective as human insulin at lowering A1C levels with lower risk of hypoglycemia, but they have significantly higher cost. Patients with one or more episodes of severe hypoglycemia (i.e., requiring assistance from others for treatment) may benefit from a short-term relaxation of glycemic targets. Several new insulin formulations have been approved recently that are associated with less risk of hypoglycemia compared with older formulations. The goals of therapy should be individualized based on many factors, including age, life expectancy, comorbid conditions, duration of diabetes, risk of hypoglycemia, cost, patient motivation, and quality of life.

Original languageEnglish (US)
Pages (from-to)29-37
Number of pages9
JournalAmerican family physician
Volume97
Issue number1
StatePublished - Jan 1 2018

Fingerprint

Type 2 Diabetes Mellitus
Outpatients
Hypoglycemia
Insulin
Blood Glucose
Long-Acting Insulin
Therapeutics
Costs and Cost Analysis
Age Factors
Life Expectancy
Hyperglycemia
Weight Gain
Motivation
Fasting
Quality of Life

All Science Journal Classification (ASJC) codes

  • Family Practice

Cite this

Howard-Thompson, A., Khan, M., Jones, M., & George, C. (2018). Type 2 Diabetes Mellitus: Outpatient Insulin Management. American family physician, 97(1), 29-37.

Type 2 Diabetes Mellitus : Outpatient Insulin Management. / Howard-Thompson, Amanda; Khan, Muneeza; Jones, Morgan; George, Christa.

In: American family physician, Vol. 97, No. 1, 01.01.2018, p. 29-37.

Research output: Contribution to journalArticle

Howard-Thompson, A, Khan, M, Jones, M & George, C 2018, 'Type 2 Diabetes Mellitus: Outpatient Insulin Management', American family physician, vol. 97, no. 1, pp. 29-37.
Howard-Thompson A, Khan M, Jones M, George C. Type 2 Diabetes Mellitus: Outpatient Insulin Management. American family physician. 2018 Jan 1;97(1):29-37.
Howard-Thompson, Amanda ; Khan, Muneeza ; Jones, Morgan ; George, Christa. / Type 2 Diabetes Mellitus : Outpatient Insulin Management. In: American family physician. 2018 ; Vol. 97, No. 1. pp. 29-37.
@article{2e4e1de464c245baa611c0b15a76778e,
title = "Type 2 Diabetes Mellitus: Outpatient Insulin Management",
abstract = "In patients with type 2 diabetes mellitus, insulin may be used to augment therapy with oral glycemic medications or as insulin replacement therapy. The American Diabetes Association suggests the use of long-acting (basal) insulin to augment therapy with one or two oral agents or one oral agent plus a glucagon-like peptide 1 receptor agonist when the A1C level is 9{\%} or more, especially if the patient has symptoms of hyperglycemia or catabolism. Insulin regimens should be adjusted every three or four days until targets of self-monitored blood glucose levels are reached. A fasting and premeal blood glucose goal of 80 to 130 mg per dL and a two-hour postprandial goal of less than 180 mg per dL are recommended. Insulin use is associated with hypoglycemia and weight gain. Insulin analogues are as effective as human insulin at lowering A1C levels with lower risk of hypoglycemia, but they have significantly higher cost. Patients with one or more episodes of severe hypoglycemia (i.e., requiring assistance from others for treatment) may benefit from a short-term relaxation of glycemic targets. Several new insulin formulations have been approved recently that are associated with less risk of hypoglycemia compared with older formulations. The goals of therapy should be individualized based on many factors, including age, life expectancy, comorbid conditions, duration of diabetes, risk of hypoglycemia, cost, patient motivation, and quality of life.",
author = "Amanda Howard-Thompson and Muneeza Khan and Morgan Jones and Christa George",
year = "2018",
month = "1",
day = "1",
language = "English (US)",
volume = "97",
pages = "29--37",
journal = "American Family Physician",
issn = "0002-838X",
publisher = "American Academy of Family Physicians",
number = "1",

}

TY - JOUR

T1 - Type 2 Diabetes Mellitus

T2 - Outpatient Insulin Management

AU - Howard-Thompson, Amanda

AU - Khan, Muneeza

AU - Jones, Morgan

AU - George, Christa

PY - 2018/1/1

Y1 - 2018/1/1

N2 - In patients with type 2 diabetes mellitus, insulin may be used to augment therapy with oral glycemic medications or as insulin replacement therapy. The American Diabetes Association suggests the use of long-acting (basal) insulin to augment therapy with one or two oral agents or one oral agent plus a glucagon-like peptide 1 receptor agonist when the A1C level is 9% or more, especially if the patient has symptoms of hyperglycemia or catabolism. Insulin regimens should be adjusted every three or four days until targets of self-monitored blood glucose levels are reached. A fasting and premeal blood glucose goal of 80 to 130 mg per dL and a two-hour postprandial goal of less than 180 mg per dL are recommended. Insulin use is associated with hypoglycemia and weight gain. Insulin analogues are as effective as human insulin at lowering A1C levels with lower risk of hypoglycemia, but they have significantly higher cost. Patients with one or more episodes of severe hypoglycemia (i.e., requiring assistance from others for treatment) may benefit from a short-term relaxation of glycemic targets. Several new insulin formulations have been approved recently that are associated with less risk of hypoglycemia compared with older formulations. The goals of therapy should be individualized based on many factors, including age, life expectancy, comorbid conditions, duration of diabetes, risk of hypoglycemia, cost, patient motivation, and quality of life.

AB - In patients with type 2 diabetes mellitus, insulin may be used to augment therapy with oral glycemic medications or as insulin replacement therapy. The American Diabetes Association suggests the use of long-acting (basal) insulin to augment therapy with one or two oral agents or one oral agent plus a glucagon-like peptide 1 receptor agonist when the A1C level is 9% or more, especially if the patient has symptoms of hyperglycemia or catabolism. Insulin regimens should be adjusted every three or four days until targets of self-monitored blood glucose levels are reached. A fasting and premeal blood glucose goal of 80 to 130 mg per dL and a two-hour postprandial goal of less than 180 mg per dL are recommended. Insulin use is associated with hypoglycemia and weight gain. Insulin analogues are as effective as human insulin at lowering A1C levels with lower risk of hypoglycemia, but they have significantly higher cost. Patients with one or more episodes of severe hypoglycemia (i.e., requiring assistance from others for treatment) may benefit from a short-term relaxation of glycemic targets. Several new insulin formulations have been approved recently that are associated with less risk of hypoglycemia compared with older formulations. The goals of therapy should be individualized based on many factors, including age, life expectancy, comorbid conditions, duration of diabetes, risk of hypoglycemia, cost, patient motivation, and quality of life.

UR - http://www.scopus.com/inward/record.url?scp=85061087328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061087328&partnerID=8YFLogxK

M3 - Article

C2 - 29365240

AN - SCOPUS:85061087328

VL - 97

SP - 29

EP - 37

JO - American Family Physician

JF - American Family Physician

SN - 0002-838X

IS - 1

ER -